San Diego – November 21, 2014 – Cooley advised the underwriters on Xenon Pharmaceuticals Inc.'s initial public offering. Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. Xenon has built a core-enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. The company now trades on The NASDAQ Global Market under the symbol "XENE."
Jefferies LLC and Wells Fargo Securities, LLC acted as the joint book-running managers and Canaccord Genuity Inc. acted as co-manager for the offering.
The Cooley corporate and securities team advising the underwriters included partners Charlie Kim, Drew Williamson and David Peinsipp, and associates Jonie Kondracki, Veer Bhavnagri, Kristin VanderPas, Nicole Hatcher and Sale Kwon.
Critical support was provided by partner Bill Christiansen and associate Michael Cooper (intellectual property); partners Natasha Leskovsek and Drew Gantt (health care and life sciences regulatory); partner Amy Wood and associate Megan Arthur (compensation and benefits); and partner Susan Cooper Philpot (tax).
Thus far in 2014, Cooley has advised on more than 90 completed public offerings including 48 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has 800 lawyers across 11 offices in the United States and China.